A great deal of attention is paid to the clinical aspects of treating residents in the waning days of their lives. But the physical space they occupy can be just as important. Here’s how some of...
REITs continue buying binge, with smaller deals on the rise
By
Elizabeth Newman
Dec 01, 2011
Despite the slow creep back toward traditional bank financing, real estate investment trusts (REITS) continued their buying sprees this fall.
I couldn’t live without…VoiceFriend
Dec 01, 2011
Jean DeThomas, executive director at Woburn, MA-based Brightview Country Club Hills, says adopting the VoiceFriend automated communications system has given the organization a brand new set of capabilities...
Computer games are helping people deal with Parkinson’s
By
John O'Connor
Dec 01, 2011
People with Parkinson’s disease may have a new tool for improving their gait and balance: computer games.
Whopping Medicaid cuts to hit nursing facilities hard
Dec 01, 2011
California has managed to gain Obama administration approval to cut the state’s Medicaid program funding by $1.4 billion. Providers soon will feel the sting of 10% reimbursement cuts.
Agreement declared void in dementia case
By
Elizabeth Newman
Dec 01, 2011
A U.S. Court of Appeals has agreed that an arbitration agreement signed by a nursing home resident with dementia is void.
Use caution evaluating CCRC applicants, legal expert warns
By
Elizabeth Newman
Dec 01, 2011
A continuing care retirement community must make sure it is using standard, uniform questions in screening applicants, experts emphasized at the LeadingAge convention.
Ask the legal expert: How can we fight removal of tax exempt status?
By
John Durso
Dec 01, 2011
John Durso, Esq., Ungaretti & Harris LLP
Hepatitis C medication early blockbuster
Dec 01, 2011
Vertex’s drug for treating hepatitis C virus, Incivek (telaprevir), is on course to smash the previous record for the biggest revenue-generating drug launch ever, analysts say.
FDA approved 35 new drugs during the latest fiscal year
By
Matthew Arnold
Dec 01, 2011
The Food and Drug Administration green-lighted a bumper crop of new medicines in fiscal year 2011. It happened due to expedited approval authorities, flexibility in clinical trial requirements and PDUFA...